These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
272 related articles for article (PubMed ID: 34110679)
1. Cost-effectiveness of precision diagnostic testing for precision medicine approaches against non-small-cell lung cancer: A systematic review. Henderson R; Keeling P; French D; Smart D; Sullivan R; Lawler M Mol Oncol; 2021 Oct; 15(10):2672-2687. PubMed ID: 34110679 [TBL] [Abstract][Full Text] [Related]
2. A Systematic Review of the Cost-Effectiveness Analyses of Anaplastic Lymphoma Kinase (ALK) Inhibitors in Patients with Locally Advanced or Metastatic Non-small Cell Lung Cancer (NSCLC). Chayab L; Konstantelos N; Leighl NB; Tadrous M; Wong WWL Pharmacoeconomics; 2023 Aug; 41(8):945-980. PubMed ID: 37268866 [TBL] [Abstract][Full Text] [Related]
3. Modeling Challenges in Cost-Effectiveness Analysis of First-Line Immuno-Oncology Therapies in Non-small Cell Lung Cancer: A Systematic Literature Review. Kongnakorn T; Sarri G; Freitag A; Marczell K; Kazmierska P; Masters E; Pawar V; Zhang X Pharmacoeconomics; 2022 Feb; 40(2):183-201. PubMed ID: 34595671 [TBL] [Abstract][Full Text] [Related]
4. Clinical effectiveness and cost-effectiveness of first-line chemotherapy for adult patients with locally advanced or metastatic non-small cell lung cancer: a systematic review and economic evaluation. Brown T; Pilkington G; Bagust A; Boland A; Oyee J; Tudur-Smith C; Blundell M; Lai M; Martin Saborido C; Greenhalgh J; Dundar Y; Dickson R Health Technol Assess; 2013 Jul; 17(31):1-278. PubMed ID: 23886301 [TBL] [Abstract][Full Text] [Related]
5. A rapid and systematic review of the clinical effectiveness and cost-effectiveness of paclitaxel, docetaxel, gemcitabine and vinorelbine in non-small-cell lung cancer. Clegg A; Scott DA; Sidhu M; Hewitson P; Waugh N Health Technol Assess; 2001; 5(32):1-195. PubMed ID: 12065068 [TBL] [Abstract][Full Text] [Related]
6. Epidermal growth factor receptor tyrosine kinase (EGFR-TK) mutation testing in adults with locally advanced or metastatic non-small cell lung cancer: a systematic review and cost-effectiveness analysis. Westwood M; Joore M; Whiting P; van Asselt T; Ramaekers B; Armstrong N; Misso K; Severens J; Kleijnen J Health Technol Assess; 2014 May; 18(32):1-166. PubMed ID: 24827857 [TBL] [Abstract][Full Text] [Related]
7. Folic acid supplementation and malaria susceptibility and severity among people taking antifolate antimalarial drugs in endemic areas. Crider K; Williams J; Qi YP; Gutman J; Yeung L; Mai C; Finkelstain J; Mehta S; Pons-Duran C; Menéndez C; Moraleda C; Rogers L; Daniels K; Green P Cochrane Database Syst Rev; 2022 Feb; 2(2022):. PubMed ID: 36321557 [TBL] [Abstract][Full Text] [Related]
8. Erlotinib and gefitinib for treating non-small cell lung cancer that has progressed following prior chemotherapy (review of NICE technology appraisals 162 and 175): a systematic review and economic evaluation. Greenhalgh J; Bagust A; Boland A; Dwan K; Beale S; Hockenhull J; Proudlove C; Dundar Y; Richardson M; Dickson R; Mullard A; Marshall E Health Technol Assess; 2015 Jun; 19(47):1-134. PubMed ID: 26134145 [TBL] [Abstract][Full Text] [Related]
9. Cost-effectiveness analysis of pembrolizumab versus chemotherapy as first-line treatment in locally advanced or metastatic non-small cell lung cancer with PD-L1 tumor proportion score 1% or greater. She L; Hu H; Liao M; Xia X; Shi Y; Yao L; Ding D; Zhu Y; Zeng S; Shen L; Huang J; Carbone DP Lung Cancer; 2019 Dec; 138():88-94. PubMed ID: 31655368 [TBL] [Abstract][Full Text] [Related]
10. Cost effectiveness of immune checkpoint inhibitors for treatment of non-small cell lung cancer: A systematic review. Ding H; Xin W; Tong Y; Sun J; Xu G; Ye Z; Rao Y PLoS One; 2020; 15(9):e0238536. PubMed ID: 32877435 [TBL] [Abstract][Full Text] [Related]
11. Adefovir dipivoxil and pegylated interferon alfa-2a for the treatment of chronic hepatitis B: a systematic review and economic evaluation. Shepherd J; Jones J; Takeda A; Davidson P; Price A Health Technol Assess; 2006 Aug; 10(28):iii-iv, xi-xiv, 1-183. PubMed ID: 16904047 [TBL] [Abstract][Full Text] [Related]
12. Economic Evaluation of Companion Diagnostic Testing for EGFR Mutations and First-Line Targeted Therapy in Advanced Non-Small Cell Lung Cancer Patients in South Korea. Lim EA; Lee H; Bae E; Lim J; Shin YK; Choi SE PLoS One; 2016; 11(8):e0160155. PubMed ID: 27483001 [TBL] [Abstract][Full Text] [Related]
13. Sugemalimab plus chemotherapy vs. chemotherapy for metastatic non-small-cell lung cancer: A cost-effectiveness analysis. Liang X; Chen X; Li H; Liu X; Li Y Front Public Health; 2023; 11():1054405. PubMed ID: 36923040 [TBL] [Abstract][Full Text] [Related]
14. Cost-effectiveness analysis of EGFR mutation testing and gefitinib as first-line therapy for non-small cell lung cancer. Narita Y; Matsushima Y; Shiroiwa T; Chiba K; Nakanishi Y; Kurokawa T; Urushihara H Lung Cancer; 2015 Oct; 90(1):71-7. PubMed ID: 26259876 [TBL] [Abstract][Full Text] [Related]
15. How are we evaluating the cost-effectiveness of companion biomarkers for targeted cancer therapies? A systematic review. Seo MK; Cairns J BMC Cancer; 2021 Sep; 21(1):980. PubMed ID: 34470603 [TBL] [Abstract][Full Text] [Related]
16. Cost-effectiveness analysis of first-line treatments for advanced epidermal growth factor receptor-mutant non-small cell lung cancer patients. Li WQ; Li LY; Chai J; Cui JW Cancer Med; 2021 Mar; 10(6):1964-1974. PubMed ID: 33626238 [TBL] [Abstract][Full Text] [Related]
17. EGFR mutation-guided use of afatinib, erlotinib and gefitinib for advanced non-small-cell lung cancer in Hong Kong - A cost-effectiveness analysis. You JHS; Cho WCS; Ming WK; Li YC; Kwan CK; Au KH; Au JS PLoS One; 2021; 16(3):e0247860. PubMed ID: 33647045 [TBL] [Abstract][Full Text] [Related]
18. A Systematic Review of Economic Evaluations Assessing the Cost-Effectiveness of Licensed Drugs Used for Previously Treated Epidermal Growth Factor Receptor (EGFR) and Anaplastic Lymphoma Kinase (ALK) Negative Advanced/Metastatic Non-Small Cell Lung Cancer. Gallacher D; Auguste P; Royle P; Mistry H; Armoiry X Clin Drug Investig; 2019 Dec; 39(12):1153-1174. PubMed ID: 31583605 [TBL] [Abstract][Full Text] [Related]
19. Cost-effectiveness analysis of pembrolizumab versus standard-of-care chemotherapy for first-line treatment of PD-L1 positive (>50%) metastatic squamous and non-squamous non-small cell lung cancer in France. Chouaid C; Bensimon L; Clay E; Millier A; Levy-Bachelot L; Huang M; Levy P Lung Cancer; 2019 Jan; 127():44-52. PubMed ID: 30642550 [TBL] [Abstract][Full Text] [Related]
20. Systematic review and modelling of the cost-effectiveness of cardiac magnetic resonance imaging compared with current existing testing pathways in ischaemic cardiomyopathy. Campbell F; Thokala P; Uttley LC; Sutton A; Sutton AJ; Al-Mohammad A; Thomas SM Health Technol Assess; 2014 Sep; 18(59):1-120. PubMed ID: 25265259 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]